News

The T-Force study is an open-label, multi-dose, two-week study of 36 subjects with Tourette syndrome. Children and adolescents will receive once-daily dosing of NBI-98854 during a two-week treatment

Prima will pay consideration of up to approximately US$28 M through a combination of cash, shares and warrants subject to the achievement of certain performance milestones. The transaction

Combined net sales of the Products during the twelve month period ending August 31, 2014 were approximately CDN$10.8 million. Fiorinal and Fiorinal C are indicated for the relief

NKTT120 is a humanised monoclonal antibody that specifically depletes iNKT cells, a regulatory T cell that has been demonstrated as a major mediator of organ damage in preclinical

Vedolizumab is a gut-selective humanized monoclonal antibody that has recently been made available in the US and the EU, and also approved in Australia under the trade name

As part of the acquisition, Bayer now owns Merck’s existing over-the-counter (OTC) business, including the global trademark and prescription rights for Claritin and Afrin. Bayer has held back

Bioceltran is focused on Protein Transduction Domain (PTD) Technology for transdermal delivery of drugs for cosmetics and pharmaceuticals. Following the signing the license deal, Quest purchased 38% ownership

The patient who arrived from Liberia, West Africa on 20 September sought for medical care at Texas Health Presbyterian Hospital of Dallas on 24 of the same month.

Under the deal, Fast Forward will provide funding to Glialogix for preclinical studies of GLX1112, a first-in-class neuroprotective therapy designed to slow the accumulation of disability in progressive